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Abstract 
 
A-type Procyanidins and Their Effects on the Aggregation of Tau 
Prevalent in Alzheimer’s Disease 
 
by 
 
Michael James Weingart 
 
Alzheimer’s disease (AD) affects over 40 million people worldwide: a 
number that is expected to grow to over 100 million by 2050.1 Despite this, 
there is a shortage of AD drugs on the market, with only five having been 
FDA approved, and no new ones since 2003.2 A major problem is that 
these drugs are merely symptomatic treatments. No drugs exist that stop 
or prevent AD. One of the hallmarks of AD are intracellular deposits of 
insoluble neurofibrillary tangles (NFTs) in neurons of the brain.3 NFTs 
are composed of aggregates of the microtubule-associated protein, tau. 
This study focuses on discovering novel treatments that prevent the 
aggregation of tau.  
Peanut skins contain large amounts of procyanidins4: molecules 
proposed to have various health benefits.5 Peanut skin extract was run 
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through high performance liquid chromatography (HPLC) to separate the 
many compounds present, in order to isolate procyanidin molecules. One 
particular procyanidin was separated and used for inhibition assays with 
tau and appeared to inhibit its aggregation into NFTs. It was then 
identified using electrospray ionization mass spectrometry (ESI-MS) and 
proton nuclear magnetic resonance (1H-NMR) to be the A1 procyanidin 
dimer isomer.  
While running HPLC to isolate more procyanidin A1 for further 
experimentation, it became apparent that one of the pumps had a leak. 
This caused a lower percentage of that pump’s solvent to go through the 
column than what it was set to. This resulted in the presumably pure 
procyanidin A1 eluting later than usual, and separating from another, 
currently unidentified, molecule. Further experimentation led to the 
conclusion that the A1 procyanidin has no effect on the aggregation of tau, 
which was backed up by tests that were then done with a commercially 
available procyanidin A1 that was purchased. It is assumed that an 
unidentified contaminant is responsible for the inhibitory activity. 
Further studies are required to find which compound is responsible for 
the inhibition seen on tau aggregation. 
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Introduction 
An ever-growing global population, paired with constant improvements 
in medicine that raise the average worldwide life expectancy, mean the 
number of cases of Alzheimer’s disease (AD) is always on the rise. Right 
now there is an estimated 44 million people with the disease worldwide, 
and the 2017 Alzheimer's disease facts and figures report projects that for 
the first time, over a quarter of a trillion dollars would be spent on AD 
related healthcare in the United States.6 Despite this, no new drugs have 
been developed for AD since 2003.2 Only five drugs have been FDA 
approved, and they all simply slow down AD progression2; none exist that 
cure or prevent it.7 Three of these, donepezil, galantamine, and 
rivastigmine, are cholinesterase inhibitors that work by inhibiting 
enzymes that degrade the neurotransmitter acetylcholine. The cholinergic 
hypothesis concludes that during the early stages of AD, there is a loss of 
acetylcholine neurons and a reduction of enzymatic function for 
acetylcholine synthesis. Cholinesterase inhibiters therefore delay the 
degradation of acetylcholine and increase cholinergic transmission. A 
fourth drug, named memantine, works as an antagonist for the N-methyl-
D-aspartate receptor that binds to glutamate. It is believed that this 
protects neurons from excitotoxicity: a process that’s associated with AD 
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as well as a variety of other neurological disorders.8 The fifth medication 
is a combination of donepezil and memantine. The problem with these 
drugs is that they are merely symptomatic treatments. Many studies are 
focusing on finding novel treatments that can prevent AD from 
progressing in the first place by targeting a possible root cause.7 
The two main neuropathological hallmarks of AD are extracellular 
amyloid plaques and intracellular neurofibrillary tangles (NFTs), both of 
which plague neurons in the brains of patients.3 Amyloid plaques are 
buildups of the protein β-amyloid in-between neurons. It is believed that 
as β-amyloid begins to cluster together, it binds to a receptor on the 
neuron surface. This biochemical signal results in a cascade within the 
cell that ultimately alters the cell’s synapses, and therefore its ability to 
communicate with other cells.9 NFTs consist of insoluble fibers of paired 
helical filaments (PHFs) that arise from misfolded aggregates of the 
highly soluble microtubule-associated protein tau.10 This study is centered 
around the search for small molecules that inhibit the aggregation of tau, 
and therefore can potentially be new therapeutics for AD. 
In humans there are six isoforms of tau, all of which are expressed via 
alternative splicing of a single gene MAPT (microtubule associated 
protein tau) that is located on chromosome 17 (figure 1).11 They range 
from 352 to 441 amino acids, and all are observed in NFTs.12 The normal 
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role of tau, which is abundant in neurons of the central nervous system13, 
is to interact with tubulin to stabilize microtubule assembly.11 In AD the 
tau is hyperphosphorylated (three or four times more phosphorylated 
than in healthy brains14) which results in the disassembly of microtubules 
and the formation of PHFs.15 PHFs interfere with cytoplasmic functions 
and axonal transport which can ultimately lead to cell death.16  
It’s possible to test the effects of molecules on the aggregation of tau by 
using light scattering. As tau aggregates together, it increases the 
turbidity of the solution, which can be detected and recorded. With 
heparin present, tau187 reaches its maximum level of aggregation in 5-6 
hours, as opposed to a minimum of several days without it (full length tau 
also takes days to aggregate, as opposed to hours with isoforms of tau that 
only include the binding repeats such as the one used in this study).17 
Two important factors to consider regarding the effectiveness of a new 
drug are toxicity and solubility. Regarding toxicity, a functional drug is of 
no use if its toxicity hurts the patient more than it helps them. As for 
solubility, a drug must be present in the form of solution in order to be 
absorbed.18 During the search for our novel drug, to get around the 
toxicity obstacle edible plants were used, and to get around the solubility 
obstacle, only the water soluble fraction was extracted and analyzed.   
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Previous work by Peterson et al. at UCSB found that a molecule 
present in cinnamon extract inhibited tau aggregation.19 Upon further 
study, it was discovered that the bioactive molecule was a trimer of 
catechin/epicatechin molecules, named a procyanidin. Procyanidins are 
members of the proanthocyanidin class of flavonoids, and are naturally 
occurring polyphenolic compounds that are present in a wide variety of 
foods such as nuts, fruits, and beans. They’re regarded as healthy 
supplements due to their supposed antioxidant, antimicrobial, and 
anticancer properties.20 
At around 867 daltons, trimeric procyanidins are above the rough 
500Da upper limit outlined in Lipinski’s rule of five, and are therefore 
likely too large to cross the blood-brain barrier (BBB), an important factor 
when determining the efficacy of new drugs.21 Because of this, a change in 
strategy was formulated. Peanut skins are known to be abundant with the 
smaller procyanidin dimers22 (576-578 Da) seen in figure 2, so the focus 
was shifted to concentrate on isolating these from unroasted peanuts. 
Their smaller size, while still over the threshold, would give them a 
higher chance of being successfully delivered to the brain. Studies by 
Serra et al. involved orally administering procyanidin-rich grape seed 
extract to rats and measuring the procyanidin concentrations in the gut 
and blood.23 The results showed that procyanidin dimers persisted during 
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gastric transport and were present in significant concentrations in the 
small and large intestine several hours after ingestion. They were also 
present in the blood, albeit at lower concentrations, at 1hr post ingestion. 
This shows that procyanidin dimers survive the harsh conditions of the 
gastrointestinal system, and are successfully absorbed into the 
bloodstream, giving them transport to the brain.  
B-type procyanidin dimers consist of two catechin/epicatechin 
monomers linked together with a 4β-8 or 4β-6 C-C bond. A-type 
procyanidins have an additional 2β-7 C-O-C bond. A-type and B-type 
procyanidins are very similar in atomic composition, differing by only two 
extra hydrogens in the B-type. Due to the four stereoisomers of 
catechin/epicatechin, and the variation in bonds possible, there are a 
number of possible procyanidin structures.  
Electrospray ionization mass spectrometry (ESI-MS) can be utilized to 
analyze molecules separated by high performance liquid chromatography 
(HPLC). Once a procyanidin is found, the molecular weight will determine 
whether it is an A-type or B-type procyanidin (576 vs 578 Da), and proton 
nuclear magnetic resonance (1H-NMR) can identify the particular isomer.  
Preliminary data from Dylan Peterson at UCSB (personal 
communication, unpublished) showed that procyanidin dimer-rich peanut 
skin extract (PSE) possibly reduces the amount of PHFs in neurons of the 
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brains of mice. Transgenic ‘AD mice’ that overexpressed human tau and 
ultimately developed AD (strain B6.Cg-Mapttm1(EGFP)KltTg(MAPT)8cPdav/J 
(005491; Jackson Labs)) were gavage-fed 100µl PSE at 30mg/mL twice a 
week starting at eight weeks of age for two months. Brain sections were 
immuno-histochemically stained with the tau NFT binding antibody MC1, 
and seemed to bind less in the PSE+ brains than in the PSE- control mice. 
Although not very convincing data in its current capacity, this suggests a 
possibility that a compound present in PSE is reducing the aggregation of 
tau within the brain. 
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Materials and Methods 
Tau Expression & Purification 
Methods of tau expression and purification were based on methods 
formulated by Peterson et al.24 A portion (residues 255 to 441) of the 
largest tau isoform ‘2N4R’ was amplified by PCR and cloned into pET28 
vector. A hexahistidine tag (MGSSHHHHHHSSGLVPRGSH) was fused to 
the N-terminus to allow purification with nickel resin. This was expressed 
in E. coli strain BL21 DE3 and named ‘tau187’.  
E.coli were grown from a glycerol stock of tau187 in 2mL LB culture to 
an OD600 of 0.6-0.8, which was then used to inoculate 200mL minimal 
media. This was grown overnight, at which point 40mL was added to 1L of 
fresh minimal media. This was grown to an OD600 of 0.6-0.8, at which 
point protein expression was induced with 1mM isopropyl β-D-1-
thiogalactopyranoside (IPTG) for 3 hours. The bacteria were then pelleted 
by centrifugation for 15min at 5000 x g in a Sorval SS-34 rotor at 4°C. The 
pellet was resuspended in 20mL lysis ‘buffer A’ (20mM MOPS [pH7.4], 
10mM imidazole, 0.1mM EDTA, 50mM NaCl, 1mM DTT), PMSF (1mM), 
lysozyme (2mg/mL), DNase (20µg/mL) and MgCl2 (1mM). The sample was 
then placed on ice and kept as cool as possible for the remainder of the 
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purification. The sample was sonicated (6 x 30sec intervals with 1min 
cooling in between each sonification) with a Branson Sonifier 250 
ultrasonic cell disruptor. The lysate was then centrifuged for 30min at 
15,000rpm (Sorval SS-34) and the supernatant was loaded onto 2mL of 
Ni-NTA agarose. The resin was then washed with buffer A, buffer B (same 
as buffer A but with 500mM NaCl), and then the tau was eluted with 
buffer C (same as buffer A but with 300mM imidazole) and collected in 
fractions. SDS-PAGE gels were then run to determine which fractions 
contained tau. These fractions were pooled and loaded onto 5mL of SP-
sepharose that was equilibrated with buffer SP-A (20mM MOPS pH 7.4, 
0.1mM EDTA, 50mM NaCl). SP-A was flowed through, followed by SP-B 
(same but with 150mM NaCl), and then the tau was eluted with SP-C 
(same but with 500mM NaCl) and collected in fractions. SDS-PAGE was 
again utilized to determine which fractions contained protein. These were 
pooled and concentrated to approximately 0.5-1mL using an Amicon ultra-
4 centrifugal filter unit. The sample was then applied to a gel filtration 
column containing sepharose CL6B and fractions were collected. Fractions 
were once more analyzed with SDS-PAGE and those containing protein 
were pooled together. These were then concentrated and stored at -80°C. 
The concentration of tau was determined by an assumed extinction 
coefficient at 274nm of 2.8cm-1mM-1 that was calculated using the known 
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extinction coefficient for tyrosine, two of which are present in tau187 
(tryptophan is absent). Tau is natively unfolded so denaturing is 
unnecessary for obtaining A274. 
Tau Aggregation Assay 
Tau aggregation assays took place in an 8-well microcell in a Shimadzu 
1601 spectrophotometer running UV probe software, measuring A350 every 
minute for up to 600min. Each well contained 50µM tau187, 100mM NaCl, 
20mM sodium phosphate buffer (pH 6.9), 0.11mg/mL heparin (Sigma 
H3393, average weight of 18kDa, used to induce rapid aggregation), 
whichever molecule (and at a particular concentration) was being tested 
for activity (dissolved in water), and water to bring it to a total of 100uL. 
An absorbance control with only water, and a negative inhibition control 
with no inhibitory molecule, were included in all assays. Procyanidin 
concentration was initially chosen to be around 50uM, only so that it 
would be equal to the tau concentration. This was calculated using an 
extinction coefficient at 279nm of 7.32cm-1mM-1. 
Preparation of PSE 
Skins were peeled off of unroasted Spanish peanuts and placed in a 
round bottom flask containing a stir bar and water preheated to 40°C. 
One gram of skins was added to 50mL of water and then stirred rapidly 
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for 10min. The mixture was then strained off, the liquid was centrifuged 
at 4°C in an SS-34 rotor at 10,000rpm to separate solid material, and then 
the supernatant was passed through a 2µm vacuum filter. This was then 
lyophilized with a Virtis 4K benchtop freeze dryer overnight. 
Isolation of Procyanidin 
Solid PSE was dissolved in water/0.1% trifleuroacetic acid (TFA) at a 
concentration of 10mg/mL. 2mL was injected onto reverse phase HPLC 
(Waters 2487 dual wavelength detector, Waters 1525 binary pump, Breeze 
software version 3.30) at flow rate 4.7mL/min. Solvents used were 
water/0.1% TFA and HPLC grade acetonitrile/0.09% TFA. A Waters 
Atlantis prep T3 column (5µm 10x250mm) with attached guard column 
was used for separation, and a Symmetry C18 Column (100Å, 3.5µm, 
3x100mm, flow rate 0.5mL/min) was used for analytical purposes. 
Solvents were initially run on a changing gradient that increased the 
acetonitrile composition over time. The peak of interest was collected, 
frozen with dry ice, lyophilized overnight, and dissolved in water/0.1% 
TFA. This was then run again on HPLC on a 15% acetonitrile isocratic 
method to further separate and purify the compound. Collected liquid was 
frozen, lyophilized, and resuspended in water. A279 was measured to 
determine concentration. 
  11 
Determination of Procyanidin Molar Extinction Coefficient 
5mg of procyanidin A2 was purchased from BOC sciences and was 
dissolved in 1mL of water, diluted 100 fold, and measured on a UV 
spectrophotometer at a wavelength of 279nm. A-type procyanidins are 
576Da so 576mg/mL = 1M. 5mg/mL therefore equals 8.68mM. Diluted 100 
fold at 86.8uM it gave an A279 of 0.635. Using Beer’s law A = ε ⋅c ⋅l, the 
molar extinction coefficient of procyanidin A2 at 279nm was calculated to 
be 7.32cm-1mM-1. It was assumed that the extinction coefficients for all A-
type and B-type procyanidin dimers would be fairly similar, since the four 
conjugated systems which are responsible for the absorbance in the UV 
range aren’t disrupted between different isomers. This is proven to be 
correct by Bohr et al.25 as they measured procyanidin dimers B2-B5 to 
have an average extinction coefficient of 7.53cm-1mM-1 with a range of 
only 1.7cm-1mM-1.  
Mass Spectrometry 
The samples were dissolved in water/0.1% formic acid and run via 
autosampler of a Waters Acquity H-class Quarternary Separations 
Module pump and Xevo G2-XS Tof MS detector. All runs were in positive 
ion mode. MassLynx software (Micromass Inc.) was used to analyze the 
data. 
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1H-NMR Spectroscopy 
Approximately 5mg of sample was dissolved in 0.5mL of deuterated 
methanol and run on a Varian Unity Inova 600 MHz spectrometer at 
room temperature. VnmrJ software was used to analyze the data. 
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Results 
When PSE was run on HPLC there were many peaks, each 
corresponding to one of the numerous different molecules present. In 
preliminary experiments involving PSE and HPLC conducted by Dylan 
Peterson prior to this study, several of the more prominent, high 
absorbing peaks were isolated and tested with mass spectrometry in order 
to find one at 576 or 578Da. It was discovered that the first prominent 
peak on the chromatogram was 576Da (unpublished data). This was 
repeated for this study and the peak was collected at approximately 
36min as pointed out in figure 3. The collected material was frozen using 
dry ice and lyophilized overnight. A beige white powder remained, and 
was dubbed ‘1X’ (one times purified). This was fully soluble in water/0.1% 
TFA and was reinjected back on to the same HPLC column. The 15% 
acetonitrile isocratic run separated the material further as seen in figure 
4. The largest peak that eluted first was collected, lyophilized, and dubbed 
‘2X’. This dried material was entirely white powder. 2X was run on HPLC 
through a C18 analytical column and appeared to be very pure (figure 5). 
This was tested in a tau aggregation assay and showed inhibition in a 
dose-dependent manner with regard to concentration, as shown in figure 
6.  
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ESI-MS was conducted on the 2X sample which revealed it to be 576 
Da, equal to the molecular weight of A-type procyanidins (figure 7). Mass 
spectrometry from the National Institute of Standards and Technology 
(NIST)26 on procyanidin A1 shows the 2nd and 4th most prominent peaks 
present to be 425Da and 287Da respectively. Experiments by Karchesy et 
al. showed that fast atom bombardment on procyanidin A1 gave 
prominent fragments of 425 and 287Da.27 These masses are the next two 
most prominent peaks on the 2X data that was obtained, which is further 
evidence that the isolated molecule is an A-type procyanidin. In the same 
study, Karchesy et al. also tested procyanidin B7 which gave peaks at 579, 
427, and 289Da. 
To determine which isomer of procyanidin was in the 2X sample, 1H-
NMR spectroscopy was conducted and compared to the findings from a 
study by Lou et al.22 in which they conducted 1H-NMR on a variety of A-
type procyanidins that they isolated from peanut skins. The results of the 
2X sample (figure 8a) most closely resembled their data for the A1 isomer 
(table 1). The A1 and A2 isomers were commercially available and 
purchased from Cerilliant Corporation and BOC Sciences, respectively. 
1H-NMR was conducted on these samples (figures 8b and 8c) and the 
results corresponded closely with the results from Lou et al. (table 1) with 
only small changes in the chemical shifts of hydrogens. It was concluded 
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from these results that the isolated 2X material was the procyanidin A1 
isomer. 
The purchased A1 dimer was tested in a tau aggregation assay at 
50µM and did not inhibit aggregation, as seen in figure 11. The green line 
shows how tau aggregation is inhibited with the addition of 50µM 2X 
sample, and the blue line shows that the addition of the purchased A1 
dimer at the same concentration has little effect on tau aggregation. The 
A2 isomer was also tested and had a similar result (data not shown). 
Since the purchased pure A1 isomer does not inhibit tau aggregation, 
there must be another unidentified molecule present that is responsible 
for the 2X sample’s inhibitive activity.  
During preparation of more 2X material, it became apparent that there 
was a leak in the pump that fed acetonitrile through the column. This 
resulted in the actual concentration of acetonitrile to be less than the set 
proportion of 15%. This caused the sample to elute later than usual. 
Acetonitrile is the hydrophobic component of the mobile phase responsible 
for moving the 1X sample molecules through the column, so a reduction in 
acetonitrile percentage resulted in a longer retention time. It also resulted 
in an increase in separation of the molecules present, so the single peak 
that was normally collected was split into two different peaks as seen in 
figure 12 at ~92min and ~102min. These separated peaks were collected 
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and analyzed with ESI-MS. This showed that the second of the peaks was 
the A1 procyanidin, and the most prominent signal for the first molecule 
was 466Da (figure 13). They were both tested on tau aggregation and the 
collected A1 procyanidin did not inhibit, while the 466Da molecule did in 
a dose dependent manner, shown in figure 14. Studies in the Lew 
laboratory are continuing in order to identify the molecule with intrinsic 
tau aggregation inhibitory activity.   
 
 
 
 
 
 
 
 
 
 
 
  17 
Discussion 
Something present in peanut skins inhibits the aggregation of tau into 
paired helical filaments, and this study shows that it isn’t procyanidin A1 
or A2, or likely any A-type procyanidin, but rather another unidentified 
molecule. This molecule must have hydrophobic properties comparable to 
procyanidin A1 since with HPLC it elutes at the same time under the 
conditions used. Changing different aspects of the overall HPLC 
configuration would likely aid in identifying this mystery molecule. 
Since the new molecule of interest is unknown, it is impossible to know 
exactly which configuration will be the best at isolating it from the many 
other molecules that are present in PSE. Instead of using acetonitrile as a 
solvent, other common solvents, such as methanol, could be used which 
interact with molecules differently. This would change the peak shape, 
the elution time of individual molecules, and the amount of time between 
the elution of each molecule (resulting in an increase or decrease in 
separation). Instead of using a C18 column where the hydrophobic carbon 
chains packed inside the column are 18 carbons long, C8 or even C4 could 
be utilized. The shorter carbon chains are less hydrophobic and so would 
reduce hydrophobic interactions with the samples. This would cause the 
hydrophobic molecules in the PSE to bind less strongly to the column 
which would change the elution times of the different molecules in the 
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sample. Reverse phase HPLC was used in the entirety of this study but 
normal phase or ion exchange may be a better choice for these particular 
samples. Since the molecule of interest is unknown, all of these 
alterations in the configuration would have to be blindly tested, but they 
may prove to be much more efficient at separation. 
Of the six 576Da A-type procyanidins analyzed by Lou et al. shown in 
figure 15 (the other compounds identified in the study were methylated 
derivatives), the 1H-NMR data for the A1 isomer most closely matches the 
data retrieved from the 2X sample. There are small differences in the 
chemical shifts of some hydrogens (an average deviation of only 0.027ppm 
per hydrogen), but this is most likely due to differences in equipment 
and/or technique and procedure. When the purchased A1 dimer was 
analyzed with 1H-NMR, the spectrum was incredibly similar to that of the 
2X sample, which implies that the 2X is the A1 procyanidin isomer. In 
fact, the two samples were virtually identical with regards to chemical 
shifts and splitting patterns. The only noteworthy difference is the 
presence of what appears to be a singlet at approximately 7.95ppm on the 
purchased A1 spectrum, but the intensity is less than 25% of that which is 
equivalent to a single proton so it does not represent the A1 that was 
being tested, but instead most likely a contaminant at a much lower 
concentration.  
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Even though the extreme similarity of the 1H-NMR spectrums for the 
2X and purchased A1 samples strongly implies that they are the same 
molecule, it is still wise to rule out isomers A2-A6 by additional means. 
Some of the equivalent hydrogens across the six isomers do not change 
much on 1H-NMR spectra due to them being in very similar 
environments. The minor changes between the isomers is enough, 
however, to see changes in the chemical shifts of certain hydrogens. To 
rule out A2, the strongest evidence is that the 1H-NMR data was obtained 
and it does not resemble that of the 2X sample. Additionally, there is only 
one doublet present at ~7.13ppm where A2 should have two. The #10 and 
#10’ hydrogens are either side of the #14 doublet of doublets while with 
A2, both #10 and #10’ are downfield from the two doublets of doublets of 
#14 and #14’ that are separated by only 0.08ppm. With A3 and A6, the 
peaks for #4and #4are no longer two separate doublets of doublets like 
the 2X sample, but instead one multiplet. For A3, as with A2, #10’ is 
alongside #10 at ~7.13 ppm. The 2X sample only has one doublet that far 
downfield. The integration on the 2X spectra shows that there are three 
protons present at ~6.8ppm, but A3 only has two in that location. A4 and 
A5 both have #14’ alone at 6.68ppm, while the sample has it at 6.80ppm 
alongside  #13’ and #13 at 6.80ppm and 6.79ppm respectively. On top of 
all of this, if one attempts to line up the data from Lou et al. (table 1) for 
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the A2-A6 isomers with the 1H-NMR spectra for the 2X sample, the 
average deviation in chemical shift is much larger than with their data for 
A1. 
The leak in the HPLC pump split the previously presumed pure 2X 
material into two: the A1 procyanidin and an unknown. Mass 
spectrometry on the unknown (figure 13) shows a peak with the highest 
intensity of mass 466.53Da. Francisco et al. isolated molecules from 
peanut skins28 and one possible match could be sodiated catechin gallate 
(442.37Da + 22.99Da). This only equals 465.36Da: a full mass unit below 
the unknown molecule’s mass. Testing this sample again with different 
combinations of solvent and ion mode would perhaps increase its 
ionizability and give better results, making it easier to identify. 
Experiments were previously performed in the Lew laboratory 
(unpublished data) on tau187 cys-mutants with which one of the sole two 
cysteines, residues cys291 or cys322, was changed to a serine (cysteine 
and serine are very similar, differing only in the switching of the thiol for 
a hydroxyl group. This change renders the protein incapable of forming 
disulfide bonds at this residue). A double mutant with both mutations was 
also used. All three mutants aggregated normally with heparin which 
shows that the cysteines aren’t required by heparin in order for it to have 
its effect on tau aggregation. When treated with an isolated sample from 
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PSE that had inhibitory activity (thought to be an A-type procyanidin at 
the time), the two single mutants were inhibited but the double mutant 
aggregated normally. These experiments rule out the possibility that the 
inhibiting molecule is interacting with heparin instead of tau, and 
strongly suggest that it interacts with cysteine. Whether cysteine is 
present or absent, the tau aggregates; but if the inhibitor is added then 
the double mutant is the only one that isn’t inhibited. The mechanism of 
action for the inhibitor requires at least one of the cysteines, and heparin 
is not targeted.  
The original aim of this study was to identify the isomer of procyanidin 
that was thought to be inhibiting tau aggregation. Due to malfunctioning 
equipment, a sample that was believed to be a pure isolate of a particular 
procyanidin turned out to contain a contaminant which could be 
responsible for the inhibitory activity. The status of the previously 
isolated procyanidin trimer also becomes questionable. Further 
experiments in the Lew laboratory will seek to find the true inhibitor of 
tau aggregation. 
 
 
 
 
  22 
References 
1. Prince M, et al. (2015). World Alzheimer Report 2015. The global 
impact of dementia. An analysis of prevalence, incidence, cost and 
trends. World Alzheimer’s Disease International. 
 
2. Cummings JL, Morstorf T, Zhong K. (2014). Alzheimer's disease 
drug-development pipeline: few candidates, frequent failures. 
Alzheimer's Research & Therapy. 6 (4), 37. 
 
3. Serrano-Pozo A, et al. (2011). Neuropathological alterations in 
Alzheimer disease. Cold Spring Harbor Perspectives in Medicine. 1, 
1-23.  
 
4. Yu J, et al. (2006). Peanut skin procyanidins: Composition and 
antioxidant activities as affected by processing. Journal of Food 
Composition and Analysis. 19, 364-371. 
 
5. Hammerstone JF, Lazarus SA, Schmitz HH. (2000). Procyanidin 
content and variation in some commonly consumed foods. The 
Journal of Nutrition. 130 (8S suppl), 2086S-2092S. 
 
6. Alzheimer's Association. (2017). 2017 Alzheimer's disease facts and 
figures. Alzheimer's & Dementia. 13 (4), 325-373. 
 
7. Yiannopoulou KG, Papageorgiou SG. (2013). Current and future 
treatments for Alzheimer’s disease. Therapeutic Advances in 
Neurological Disorders. 6 (1), 19-33. 
 
8. Dingledine R, et al. (1999). The glutamate receptor ion channels. 
Pharmacological Reviews. 51 (1), 7-62. 
 
9. Selkoe DJ, Hardy J. (2016). The amyloid hypothesis of Alzheimer’s 
disease at 25 years. EMBO Molecular Medicine. 8 (6), 595-608.  
 
10. Brion J. (1998). Neurofibrillary tangles and Alzheimer’s disease. 
European Neurology. 40, 130-140.  
 
11. Wang Y, Mandelkow E. (2015). Tau in physiology and pathology. 
Nature Reviews Neuroscience. 17, 22-35. 
 
  23 
12. Andreadis A. (2005). Tau gene alternative splicing: expression 
patters, regulation and modulation of function in normal brain and 
neurodegenerative diseases. Biochimica et Biophysica Acta. 1739 (2-
3), 91-103. 
 
13. Bakota L, Brandt R. (2016). Tau biology and tau-directed therapies 
for Alzheimer’s disease. Drugs. 76, 301-313.  
 
14. Jouanne M, Rault S, Voisin-Chiret A. (2017). Tau protein 
aggregation in Alzheimer's disease: An attractive target for the 
development of novel therapeutic agents. European Journal of 
Medicinal Chemistry. 139, 153-167.  
 
15. Godyn J, et al. (2016). Therapeutic strategies for Alzheimer’s 
disease in clinical trials. Pharmacological Reports. 68, 127-138. 
 
16. Mudher M, Lovestone S. (2002). Alzheimer's disease - do tauists 
and baptists finally shake hands? Trends Neuroscience. 25, 22-26.  
  
17. Barghorn S, Mendelkow E. (2002). Toward a unified scheme for the 
aggregation of tau into Alzheimer paired helical filaments. 
Biochemistry. 41 (50), 14885-14896. 
 
18. Ketan T, et al. (2012). Drug solubility: Importance and 
enhancement techniques. ISRN Pharmaceutics. 2012 (article ID 
195727), 1-10.  
 
19. Peterson D, et al. (2009). Cinnamon extract inhibits tau 
aggregation associated with Alzheimer's disease in vitro. Journal of 
Alzheimer's Disease. 17, 585-597.  
 
20. Prior RL, Gu L. (2005). Occurrence and biological significance of 
proanthocyanidins in the American diet. Phytochemistry. 66 (18), 
2264-2280.  
 
21. Lipinski CA, et al. (1997). Experimental and computational 
approaches to estimate solubility and permeability in drug 
discovery and development settings. Advanced Drug Delivery 
Reviews. 46 (1-3), 3-26. 
 
 
  24 
22. Lou H, et al. (1999). A-Type proanthocyanidins from peanut skins. 
Phytochemistry. 51, 297-308. 
 
23. Serra A, et al. (2010). Bioavailability of procyanidin dimers and 
trimers and matrix food effects in in vitro and in vivo models. 
British Journal of Nutrition. 103, 944-952. 
 
24. Peterson D, et al. (2008). A soluble oligomer of tau associated with 
fiber formation analyzed by NMR. Biochemistry. 47 (28), 7393-7404. 
 
25. Rohr GE, Meier B, Sticher O. (2000). Analysis of procyanidins. In 
Atta-ur-Rahman (Ed.), Bioactive Natural Products. Volume 21 (B), 
p546. 
 
26. National Institute of Standards and Technology (NIST) mass 
spectral library v17. 
 
27. Karchesy JJ, et al. (1986). Sequencing procyanidin oligomers by 
fast atom bombardment mass spectrometry. Analytical Chemistry. 
58, 2563-2567. 
 
28. Francisco ML, Resurreccion AV. (2008). Functional components in 
peanuts. Critical Reviews in Food Science and Nutrition. 48, 715-
746.  
 
 
  25 
 
Figure 1. Alternative splicing of MAPT gene that encodes for the six 
isoforms of tau. Exons 2, 3, and 10 are alternatively spliced giving six 
combinations. ‘R’ exons are the conserved sequences of microtubule 
binding repeats. Tau187 begins 14 amino acids in from the first repeat and 
aggregates more rapidly than wild type tau. Image obtained from Wang et 
al.11  
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Figure 2. Structures of stereoisomers of catechin (290Da) and 
procyanidins A1 (576Da) and B1 (578Da). A-type procyanidins are 
composed of two catechin and/or epicatechin molecules joined with two 
covalent bonds while B-type procyanidins are joined with only one. Both 
A1 and B1 consist of (-)-epicatechin and (+)-catechin. Other procyanidins 
consist of variations of catechin stereoisomers and location of linkage(s).  
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Figure 3. HPLC chromatogram of PSE on C18 semi-prep column. 
Absorbance wavelength is 214nm. Blue shows % composition acetonitrile. 
Red markers show peak of interest that was collected and purified 
further. 
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Figure 4. HPLC chromatogram of 1X sample on C18 semi-prep column. 
Major peak at 48min is peak of interest that was collected. Absorbance 
wavelengths are black-214nm, red-280nm. Blue shows % composition 
acetonitrile. 
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Figure 5. HPLC chromatogram of isolated 2X sample on C18 analytical 
column. Black is absorbance at 280nm. Blue shows % composition 
acetonitrile. 
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Figure 6. Absorbance spectrum of tau aggregation with isolated 2X 
sample. Wavelength is 350nm. 
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Figure 7. Mass spectrometry of isolated 2X sample. Major peak is 577Da 
corresponding to protonated A-type procyanidin (576Da). Secondary peaks 
are present at 425Da and 287Da. 
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Figure 8. 1H-NMR spectrums of A) 2X isolated procyanidin from PSE, B) 
purchased procyanidin A1, and C) purchased procyanidin A2. Major peaks 
at ~3.3 and ~4.85ppm are the solvent (CD3OD). 
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Figure 11. Absorbance spectrum of tau aggregation with purchased 
procyanidin A1 dimer at 50µM and isolated 2X at 50µM as positive 
control. Wavelength is 350nm. Differences in absorbances of equivalent 
samples across different spectra is due to the usage of different tau 
preparations. 
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Figure 12. HPLC chromatogram of 1X sample on semi-prep column. 
Absorbance at 214nm. Acetonitrile concentration set to 15% but is lower 
due to pump leak. Leak led to single peak from figure 4 (at ~48min) to be 
split into two peaks. Mass spectrometry determined the second peak to be 
the procyanidin and the first to be an unknown molecule, possibly 466Da 
as seen in figure 13. 
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Figure 13. Mass spectrometry of first peak in figure 12. No procyanidin is 
present. Most abundant molecule is 466Da. 
 
 
 
 
 
  
 
  36 
 
Figure 14. Absorbance spectrum of tau aggregation with sample ‘466’ 
added at arbitrary amounts of 2, 5 and 10µL of stock solution. Molecule is 
unknown but using extinction coefficient for procyanidin A2 it would be 
the equivalent of 33, 84, and 167µM. Wavelength is 350nm. 
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Figure 15. Procyanidins A1 through A6 structures from Lou et al.22 All 
have the A-type 2β-7 linkage. Structures 1-3 have a 4β-8 linkage and 4-6 
have a 4β-6 linkage. Image was edited to include numbering for all 
carbons.  
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Table 1. 1H-NMR data of A-type procyanidins 1-6 from study by Lou et 
al.22 Units are ppm. s = singlet, d = doublet, dd = doublet of doublets, m = 
multiplet, br.s = broad singlet. 
 
